Can-Fite reports Q2 2026 results and Phase III liver cancer update
Can-Fite reports Q2 2026 financial results and ongoing clinical progress in its pivotal Phase III liver cancer study.
Story updates
12:27:22 PM UTC
SquawkNews
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) TASE:CANF, a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results fo…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.